Trial intelligence / Profile preview

Methotrexate in Erosive Inflammatory Osteoarthritis (MERINO)

2019-004641-33Phase 4Active

Sponsor
Diakonhjemmet Sykehus
Start
Sep 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, double-blind trial in erosive hand osteoarthritis (EHOA) comparing Methotrexate with Placebo (2 arms). Primary endpoint: Finger joint pain VAS at 6 months. Started Sep 2020; status: active.

02

Drugs

methotrexate
03

Conditions

erosive hand osteoarthritis (EHOA)

Beyond the preview

Go deeper on 2019-004641-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2019-004641-33.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call